Fig. 5: Differentially expressed genes upon PPARα activation.

a Volcano plots (p value by fold changes (in log2 scale) of differential gene expression in the DG of PPARα−/− mice (n = 4) and WT littermates (n = 4). b Heat map showing the top 30 most significantly upregulated or downregulated genes by PPARα deficiency. c GO enrichment analysis (MF) based on all differentially expressed genes. d Relative gene expression measured by quantitative real-time PCR of selected downregulated genes. Slc25a34: t(5) = 8.102 p = 0.0005; Kdf1: t(5) = 1.160 p = 0.2984; Npsr1: t(5) = 2.678 p = 0.0439; Prsss8: t(5) = 0.4249 p = 0.6886; Vgll2: t(5) = 1.181 p = 0.2908; Rxfp1: t(5) = 3.004 p = 0.0300; NTS: t(5) = 3.779 p = 0.0129; Nxph3: t(5) = 6.446 p = 0.0013; Cdk1: t(5) = 2.682 p = 0.0437; Nxph4: t(5) = 5.155 p = 0.0036. PPARα−/−, n = 4; WT, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 compared with WT. e Activation of PPARα by intra-DG aspirin infusion increased transcriptional expression of Npsr1. relative gene expression profiles of Npsr1, Rfxp1, NTS, Nxph3 and Nxph4 in WT and PPARα−/− mice treated with intra-DG infusion of aCSF and aspirin. Npsr1: F (3, 28) = 5.169, p = 0.0057; Rxfp1: F (3, 28) = 1.693, p = 0.1911; NTS: F (3, 28) = 1.650, p = 0.2004; Nxph3: F (3, 28) = 3.276, p = 0.0356; Nxph4: F (3, 28) = 1.769, p = 0.1760; WT + aCSF, n = 8; WT + Aspirin, n = 9; PPARα−/− + aCSF, n = 8, PPARα−/− + Aspirin, n = 7. *p < 0.05 compared with WT + aCSF. Data are presented as mean ± s.e.m.